She says people on GLP-1s often skip ordering when they aren't hungry, and explains why she sees that as a problem when eating out.
Recap by typeshit. Video by NutritionBabe on TikTok.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
A short podcast clip with Terry Dubrow talks up retatrutide's commercial potential. Little detail beyond the bold money claim.
Among about 1,440 users, 56.8% of second-eye events came within six months versus 40.6% for non-users. Researchers stress it shows an association, not cause.
Loading…